- Reuters•6 hours ago
PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.
- Motley Fool•2 days ago
MannKind plans to more than double its sales force and air TV commercials plus more to increase Afrezza sales. Will this plan work?
- Zacks•2 days ago
Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||40.00 - 40.37|
|52 Week Range||36.81 - 44.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.35|
|Dividend & Yield||1.66 (4.08%)|
|1y Target Est||N/A|